** Shares of women’s health firm Daré Bioscience DARE.O rise 88% to $4.72
** Stock set for best day in over 5 years, if gains hold
** Co says its medical device, Ovaprene, showed a pregnancy rate of about 9% among participants, in an ongoing late-stage study, in line with previous results
** Ovaprene is an investigational, hormone-free, monthly intravaginal device to prevent pregnancy
** An independent safety board reviewed the data and recommended the study continue without changes, co says
** Vaginal odor was the main side effect, leading 17% of participants to leave the study
** Ovaprene works by releasing a non-hormonal agent that slows sperm and uses a polymer barrier to block them from reaching the cervix
** Including session moves, stock up 50% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。